Published online Jan 28, 2022. doi: 10.3748/wjg.v28.i4.500
Peer-review started: October 22, 2021
First decision: December 1, 2021
Revised: December 11, 2021
Accepted: January 13, 2022
Article in press: January 13, 2022
Published online: January 28, 2022
Processing time: 92 Days and 2 Hours
Evaluation of response to chemotherapy in colorectal cancer patients with synchronous liver metastases is important in terms of treatment management. In this Letter to the Editor, several issues in the article are discussed. For the comparison of carbohydrate antigen 19-9 (CA19-9) values referenced in the study, the patient group was not matched for cancer stage. Therefore, it may be more appropriate to select and compare CA19-9 values in patients with same-stage cancer.
Core Tip: It is important to evaluate synchronous liver metastases of colorectal cancer (CRC) and to determine the response to chemotherapy in patients. Based on findings from such, the optimal treatment method is selected for each patient. The scoring system described in the study, created through a combination of radiology and laboratory parameters, can guide treatment. However, we think that it would be more appropriate to discuss the results of this study in the context of other studies conducted with patients with stage IV CRC.
- Citation: Demirli Atici S, Kamer E. Is CA19-9 effective in predicting chemotherapeutic response in patients with synchronous liver metastases with colorectal cancer? World J Gastroenterol 2022; 28(4): 500-501
- URL: https://www.wjgnet.com/1007-9327/full/v28/i4/500.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i4.500
Ma et al[1] recently published a retrospective study on the emerging role of a magnetic resonance imaging (MRI)-radiomics signature to detect the predictive efficiency of models for chemotherapeutic response in colorectal cancer (CRC) patients with synchronous liver metastasis (SLM) and avoid ineffective chemotherapy.
Carbohydrate antigen 19-9 (CA19-9) has been routinely studied in patients with CRC, and in the study by Ma et al[1] the measurement of CA19-9 was found to be significant between the disease non-response (non-DR) and disease response (DR) to chemotherapy groups (P = 0.045). The authors showed that CA19-9 Levels were higher in the DR (63.3%) group than in the non-DR group (43.4%). The authors reported that CA19-9 is a promising indicator for predicting response to chemotherapy, citing the study by Zhou et al[2]. However, the study design used by Zhou et al[2] had included patients with stage III CRC, while the study by Ma et al[1] focused on patients with stage IV CRC.
Although it is known that high CA19-9 Levels are a poor-prognosis factor in untreated stage IV CRC patients, routine measurement of CA19-9 in colon cancers is not recommended by the American Society of Clinical Oncology (ASCO) guidelines due to insufficient evidence[3,4]. As such, we believe that it would be more appropriate to discuss the results of the study by Ma et al[1] in the context of other studies conducted with stage IV CRC patients[4,5].
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: Turkey
Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: Camacho S, Liu Z, Ros J, Wan XH S-Editor: Gong ZM L-Editor: A P-Editor: Gong ZM
1. | Ma YQ, Wen Y, Liang H, Zhong JG, Pang PP. Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer. World J Gastroenterol. 2021;27:6465-6475. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
2. | Zhou W, Yang F, Peng J, Wang F, Lin Y, Jiang W, Yang X, Li L, Lu Z, Wan D, Pan Z, Fan W. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy. J Cancer. 2019;10:3810-3818. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis (1)] |
3. | Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1057] [Cited by in F6Publishing: 1042] [Article Influence: 57.9] [Reference Citation Analysis (0)] |
4. | Hidaka E, Maeda C, Nakahara K, Wakamura K, Ishiyama Y, Shimada S, Seki J, Takano Y, Oae S, Enami Y, Sawada N, Ishida F, Kudo SE. High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer. Gastrointest Tumors. 2019;5:117-124. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
5. | Yu Z, Chen Z, Wu J, Li Z, Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS One. 2017;12:e0188139. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis (0)] |